Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction

Laboratory Investigation

Volumn 94, Issue 6, 2014, Pages 598-607

  Min, Hye Sook ^a   Kim, Jung Eun ^a   Lee, Mi Hwa ^a   Song, Hye Kyoung ^a   Kang, Young Sun ^a   Lee, Mi Jin ^a   Lee, Ji Eun ^b   Kim, Hyun Wook ^b   Cha, Jin Joo ^a   Chung, Young Yoon ^a   Hyun, Young Youl ^c   Han, Jee Young ^d   Cha, Dae Ryong ^a  

^a Korea University College of Medicine   (South Korea)

^b Wonkwang University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Inha University   (South Korea)

Author keywords

DPPIV; fibrosis; inflammation; LC15 0444; UUO

Indexed keywords

8 ISOPROSTANE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LC 15 0444; SMAD2 PROTEIN; SMAD3 PROTEIN; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FIBROSING ALVEOLITIS; KIDNEY FUNCTION; MOUSE; MOUSE MODEL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; URETER OBSTRUCTION; URINARY EXCRETION;

ANIMALS; CYTOKINES; DINOPROST; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FIBROSIS; KIDNEY; KIDNEY DISEASES; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PIPERIDONES; PROTEINURIA; PYRIMIDINES; STATISTICS, NONPARAMETRIC; URETERAL OBSTRUCTION;

EID: 84904172623     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.50     Document Type: Article

References (39)

1. Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci 2013;124: 17-26.
2. Simsek S, de Galan BE. Cardiovascular protective properties of incretinbased therapies in type 2 diabetes. Curr Opin Lipidol 2012;23:540-547.
3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
4. Jeffery CJ. Moonlighting proteins. Trends Biochem Sci 1999;24:8-11.
5. Ejiri S. Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc finger protein R1-associated nuclear localization. Biosci Biotechnol Biochem 2002;66:1-21.
6. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53-73.
7. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.
8. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney Blood Press Res 2012;36:65-84.
9. Proost P, Struyf S, Couvreur M, et al. Post-translational modifications affect the activity of the human monocyte chemotactic proteins MCP- 1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J Immunol 1998;160:4034-4041.
10. Heymann E, Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett 1978;91:360-364.
11. Marchetti C, Di Carlo A, Facchiano F, et al. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia 2012; 55:236-244.
12. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5: 331-342.
13. Penfold SA, Coughlan MT, Patel SK, et al. Circulating high-molecularweight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 2010;78:287-295.
14. Tiruppathi C, Miyamoto Y, Ganapathy V, et al. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J Biol Chem 1990;265:1476-1483.
15. Tinoco AD, Tagore DM, Saghatelian A. Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform. J Am Chem Soc 2010;132:3819-3830.
16. Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuria associated tubulointerstitial fibrosis inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005;16:2063-2072.
17. Lim KS, Cho JY, Kim BH, et al. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. Br J Clin Pharmacol 2009;68:883-890.
18. Mega C, de Lemos ET, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011;2011:1-12.
19. Glorie LL, Verhulst A, Matheeussen V, et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2012;303:F681-F688.
20. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012;340:248-255.
21. Chaykovska L, von Websky K, Rahnenführer J, et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One 2011;6:e27861.
22. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2,4]triazolo[4,3-A] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48: 141-151.
23. Lim KS, Kim JR, Choi YJ, et al. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a doseblock-randomized, double-blind, placebocontrolled, ascending single-dose, phase I study. Clin Ther 2008;30: 1817-1830.
24. Rhee EJ, Lee WY, Yoon KH, et al. A multicenter, randomized, placebocontrolled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:1113-1119.
25. Yang SJ, Min KW, Gupta SK, et al. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:410-416.
26. Rhee EJ, Lee WY, Min KW, et al. Gemigliptin Study 006 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obes Metab 2013;15:523-530.
27. Rizzo MR, Barbieri M, Marfella R, et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
28. Busso N, Wagtmann N, Herling C, et al. Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005;166:433-442.
29. Ning XH, Ge XF, Cui Y, et al. Ulinastatin inhibits unilateral ureteral obstruction-induced renal interstitial fibrosis in rats via transforming growth factor b (TGF-b)/Smad signalling pathways. Int Immunopharmacol 2013;15:406-413.
30. Shinosaki T, Kobayashi T, Kimura K, et al. Involvement of dipeptidyl peptidase IV in immune complex-mediated glomerulonephritis. Lab Invest 2002;82:505-513.
31. Wu H, Ma J, Wang P, et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 2010;21:1878-1890.
32. Wright EJ, McCaffrey TA, Robertson AP, et al. Chronic unilateral ureteral obstruction is associated with interstitial fibrosis and tubular expression of transforming growth factor-beta. Lab Invest 1996; 74:528-537.
33. Vaughan Jr ED, Marion D, Poppas DP, et al. Pathophysiology of unilateral ureteral obstruction: studies from Charlottesville to New York. J Urol 2004;172:2563-2569.
34. Kajiyama H, Shibata K, Ino K, et al. Possible involvement of SDF- 1alpha/CXCR4-DPPIV axis in TGF-beta1-induced enhancement of migratory potential in human peritoneal mesothelial cells. Cell Tissue Res 2007;330:221-229.
35. Sorrell JM, Brinon L, Baber MA, et al. Cytokines and glucocorticoids differentially regulate APN/CD13 and DPPIV/CD26 enzyme activities in cultured human dermal fibroblasts. Arch Dermatol Res 2003;295:160-168.
36. Frkiaer J, Knudsen L, Nielsen AS, et al. Enhanced intrarenal angiotensin II generation in response to obstruction of the pig ureter. Am J Physiol 1992;263:F527-F533.
37. Sasaki M, Shikata K, Okada S, et al. The macrophage is a key factor in renal injuries caused by glomerular hyperfiltration. Acta Med Okayama 2011;65:81-89.
38. Vaziri ND, Bai Y, Ni Z, et al. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther 2007;323:85-93.
39. Forbes MS, Thornhill BA, Galarreta CI, et al. Chronic unilateral ureteral obstruction in the neonatal mouse delays maturation of both kidneys and leads to late formation of atubular glomeruli. Am J Physiol Renal Physiol 2013;305:F1736-F1746.